Bahaa Mustafa

Assistant professor, Applied Science Private University

UAMS

Also affiliated: University of Missouri–Kansas City (2021–2024)

Formerly Arkansas Assistant professor, UAMS through 2025; now Assistant professor, Applied Science Private University.

5 h-index 15 pubs 105 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Bahaa Mustafa's research focuses on the development of novel therapeutic strategies, particularly in the field of cancer immunotherapy. His work involves the discovery and design of peptide-based inhibitors targeting immune checkpoints, such as Programmed Cell Death 1 Ligand 1 (PD-L1) and CD47. These efforts aim to enhance the body's immune response against cancer cells.

Mustafa has investigated the potential of cyclic peptides and human domain antibodies as inhibitors of PD-L1 for cancer immunotherapy. His research also extends to exploring synergistic approaches, such as combining oncolytic viruses with immune checkpoint blockade to improve treatment outcomes in models of hepatocellular carcinoma and pancreatic cancer. Additionally, he has explored the development of small peptides to inhibit SARS-CoV-2 infectivity.

Metrics

h-index: 5
Publications: 15
Citations: 105

Positions

Assistant professor 2025–present

Applied Science Private University Pharmaceutical sciences and pharmaceutics ORCID
Assistant professor 2022–2025

University of Arkansas for Medical Sciences Pharmaceutical Sciences ORCID

Selected Publications

Pancreatic tumor microenvironment reprogramming via alloantigen-expressing virotherapy elicits tumor rejection and improves immunotherapy response (2026)

Journal for ImmunoTherapy of Cancer DOI OpenAlex
Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)

Frontiers in Immunology 1 citation DOI OpenAlex
Abstract B022: Reprogramming Apoptotic Resistance in PDAC Through Synthetic Oncolytic Immunotherapy (2025)

Cancer Research DOI OpenAlex
Abstract 2155: Phage display discovery of Trop-2 peptide for targeted liposomal chemo-immunotherapy in lung cancer (2025)

Cancer Research DOI OpenAlex
Abstract 945: Live attenuated MMR vaccines modulate tumor immune cell infiltration and synergize with standard of care to prolong survival in preclinical HCC models (2025)

Cancer Research DOI OpenAlex
Abstract 947: Engineering a synthetic oncolytic virus to overcome apoptotic resistance and induce immunogenic cell death in pancreatic ductal adenocarcinoma (2025)

Cancer Research DOI OpenAlex
Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade (2024)

Molecular Therapy Oncology 5 citations DOI OpenAlex
Anti-CD47 Peptide Combined with Oncolytic Vesiculovirus-Driven Intratumoral Immunotherapy for Colorectal Cancer (2024)

American Journal of Pharmaceutical Education DOI OpenAlex
Enhancing Neoadjuvant Virotherapy’s Effectiveness by Targeting Stroma to Improve Resectability in Pancreatic Cancer (2024)

Biomedicines 6 citations DOI OpenAlex